


CLAIM AMENDMENTS

Claim 1 (canceled).

Claim 2 (previously presented) A compound of the formula



or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein:

X is Cl, Br, I, or F;

Y is =O or =NOR⁵,

R¹ is (4- to 10-membered heterocyclic) C₁-C₆ alkyl, wherein the heterocyclic is substituted by 4- to 10-membered heterocyclic,

R² is C₁-C₁₀ alkyl or C₂-C₁₀ alkenyl,


R³ is C₁-C₆ alkyl,

R⁴ is ethyl,

R⁵ is C₁-C₆ alkyl, and

R⁶ is H.

Claim 3 (currently amended) A compound of claim 2 [1] of the formula



or a pharmaceutically acceptable salt thereof wherein:

Y is =O or =NOR⁵;

R² is C₁-C₁₀ alkyl or C₂-C₁₀ alkenyl; and


R⁶ is H, -C(O)C₁-C₆ alkyl, benzyl, benzyloxycarbonyl, or (C₁-C₆ alkyl)₃ silyl.

Claim 4 (original) The compound of claim 3 wherein Y is =O and R⁶ is H.

Claim 5 (original) The compound of claim 3 wherein Y is =NOR⁵ and R⁶ is H.

Claim 6 (original) The compound of claim 4 wherein R² is CH₃, CH₂CH₃, CH₂CH=CH₂, *trans*-CH₂CH=CHCH₃, *trans*-CH₂CH=CHCH₂CH₃, or *trans*-CH₂-CH=C(CH₃)CH₂CH₂CH=(CH₃)CH₃.

Claim 7 (previously presented) A method of preparing a compound of formula I



or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein:

X is Cl, Br, I, or F;

Y is =O, or =NOR⁵; or Y means both -H and -OR⁵; or both -H and -NR⁵R¹⁰;

R¹, R², and R³ are independently selected from the group consisting of H, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, (4- to 10-membered heterocyclic) C₁-C₆ alkyl, (4- to 10-membered heterocyclic) C₂-C₆ alkenyl, (4- to 10-membered heterocyclic) C₂-C₆ alkynyl, (C₆-C₁₀ aryl) C₁-C₆ alkyl, (C₆-C₁₀ aryl) C₂-C₆ alkenyl, and (C₆-C₁₀ aryl) C₂-C₆ alkynyl wherein said alkyl moieties of the foregoing groups are optionally substituted by halo or C₁-C₆ alkyl, and wherein said heterocyclic moieties are optionally substituted by 4- to 10-membered heterocyclic, (4- to 10-membered

heterocyclic) C₁-C₆ alkyl, or (C₆-C₁₀ aryl) C₁-C₆ alkyl, and further wherein the aryl and heterocyclic moieties of each of the foregoing groups and optional substituents is optionally substituted by 1 to 4 R⁷ groups;

R⁴ is selected from the group consisting of H, C₁-C₁₀ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, (C₁-C₆ alkoxy) C₁-C₆ alkyl, (C₁-C₆ alkylthio) C₁-C₆ alkyl, (C₅-C₈ cycloalkyl) C₂-C₅ alpha branched alkyl, C₃-C₈ cycloalkyl, C₅-C₈ cycloalkenyl, 3 to 6 membered O or S containing heterocyclic group, or phenyl, wherein each R⁴ group may be substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxy, halo, (C₆-C₁₀ aryl) C₂-C₆ alkenyl, and C₁-C₄ alkyl;


R⁵ and R¹⁰ are independently selected from the group consisting of H, C₁-C₆ alkyl, C₆-C₁₀ aryl, 4- to 10-membered heterocyclic, (4- to 10-membered heterocyclic) C₁-C₆ alkyl and (C₆-C₁₀ aryl) C₁-C₆ alkyl, wherein said aryl and heterocyclic groups are optionally substituted by 1 to 4 R⁷ groups;

R⁶ is H, -C(O)C₁-C₆ alkyl, benzyl, benzyloxycarbonyl, or (C₁-C₆ alkyl)₃ silyl;

R⁷ is independently selected from the group consisting of halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -C(O)R⁸, -C(O)OR⁸, -OC(O)R⁸, -NR⁸C(O)R⁹, -C(O)NR⁸R⁹, -NR⁸R⁹, hydroxy, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₆-C₁₀ aryl, 4- to 10-membered heterocyclic, and C₁-C₆ alkoxy; and


each R⁸ and R⁹ is independently selected from the group consisting of H, C₁-C₆ alkyl, C₆-C₁₀ aryl, and 4- to 10-membered heterocyclic;

which comprises deprotecting a compound of the formula



wherein P is a protecting group.

Claim 8 (previously presented) The method of claim 7 further wherein the compound of formula II is prepared by treating a compound of the formula



with a strong base and a compound of formula $R^2\text{-}L$,

wherein L is a leaving group, and wherein

R^2 is selected from the group consisting of $C_1\text{-}C_{10}$ alkyl, $C_2\text{-}C_{10}$ alkenyl, $C_2\text{-}C_{10}$ alkynyl, (4- to 10-membered heterocyclic) $C_1\text{-}C_6$ alkyl, (4- to 10-membered heterocyclic) $C_2\text{-}C_6$ alkenyl, (4- to 10-membered heterocyclic) $C_2\text{-}C_6$ alkynyl, ($C_6\text{-}C_{10}$ aryl) $C_1\text{-}C_6$ alkyl, ($C_6\text{-}C_{10}$ aryl) $C_2\text{-}C_6$ alkenyl, and ($C_6\text{-}C_{10}$ aryl) $C_2\text{-}C_6$ alkynyl wherein said alkyl moieties of the foregoing groups are optionally substituted by halo or $C_1\text{-}C_6$ alkyl, and wherein said heterocyclic moieties are optionally substituted by 4- to 10-membered heterocyclic, (4- to 10-membered heterocyclic) $C_1\text{-}C_6$ alkyl, or ($C_6\text{-}C_{10}$ aryl) $C_1\text{-}C_6$ alkyl, and further wherein the aryl and heterocyclic moieties of each of the foregoing groups and optional substituents is optionally substituted by 1 to 4 R^7 groups.

Claim 9 (previously presented) A pharmaceutical composition for the treatment of a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises a therapeutically effective amount of a compound of claim 2, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, and a pharmaceutically acceptable carrier.

Claim 10 (previously presented) A method of treating a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises administering to said mammal, fish or bird a therapeutically effective amount of a compound of claim 2, or a pharmaceutically acceptable salt, prodrug, or solvate thereof.